XPO-1 in Combination With RCHOP for DH/TH Lymphoma

Sponsor
Zhejiang Cancer Hospital
Study ID
NCT05974085
Phase
PHASE2
Status
Unknown

Conditions

  • Double Hit Lymphoma
  • Triple Hit Lymphoma

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Selinexor+RCHOP — DRUG
    XPO-1 inhibitor selinexor in combination with RCHOP

Study Details

The purpose of this study was to evaluate the efficacy and safety of Selinexor in combination with RCHOP in first-line treatment of patients with DH or TH lymphoma.

Key Dates

Start date
Aug 1, 2022
Status verified
Aug 2023
Primary completion
Dec 31, 2023
Completion
Mar 1, 2024

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Selinexor+RCHOP
    Selinexor: 60 mg QW Rituximab: 375 mg/m2, d0 Vincristine: 4 mg, d1 Epirubicin: 75 mg/m2, d1 or Liposomal doxorubicin: 35 mg/m2, d1 Cyclophosphamide: 750 mg/m2, d1 Prednisone: 100 mg, d1-5

Primary Outcome Measure

Objective Response Rate [ Time Frame: From date of first day of treatment until the date of last day of treatment ]

Central Contacts